A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel inBRCA1/2metastatic breast cancer: design and rationale
出版年份 2017 全文链接
标题
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel inBRCA1/2metastatic breast cancer: design and rationale
作者
关键词
-
出版物
Future Oncology
Volume 13, Issue 4, Pages 307-320
出版商
Future Medicine Ltd
发表日期
2016-10-14
DOI
10.2217/fon-2016-0412
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- (2016) Hope S. Rugo et al. NEW ENGLAND JOURNAL OF MEDICINE
- 102PD * A RANDOMIZED, DOUBLE-BLIND, PHASE 2 TRIAL OF VELIPARIB (ABT-888) WITH CARBOPLATIN AND PACLITAXEL IN PREVIOUSLY UNTREATED METASTATIC OR ADVANCED NON-SMALL CELL LUNG CANCER
- (2015) J. Mazieres et al. ANNALS OF ONCOLOGY
- PARP inhibitors in the management of breast cancer: current data and future prospects
- (2015) Luca Livraghi et al. BMC Medicine
- A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
- (2015) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).
- (2015) Shalu Pahuja et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
- (2015) Steven J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
- (2015) T. A. Hopkins et al. MOLECULAR CANCER RESEARCH
- Profile of veliparib and its potential in the treatment of solid tumors
- (2015) Lars Wagner OncoTargets and Therapy
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
- (2014) F. Cardoso et al. BREAST
- Protein ADP-ribosylation and the cellular response to DNA strand breaks
- (2014) K.W. Caldecott DNA REPAIR
- Poly(ADP-ribose) polymerases in double-strand break repair: Focus on PARP1, PARP2 and PARP3
- (2014) Carole Beck et al. EXPERIMENTAL CELL RESEARCH
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Targeting the DNA Repair Pathway in Ewing Sarcoma
- (2014) Elizabeth Stewart et al. Cell Reports
- Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
- (2013) Peter Bouwman et al. CLINICAL CANCER RESEARCH
- The recognition and removal of cellular poly(ADP-ribose) signals
- (2013) Eva Barkauskaite et al. FEBS Journal
- Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
- (2013) Nicola J. Curtin et al. MOLECULAR ASPECTS OF MEDICINE
- Structural biology of the writers, readers, and erasers in mono- and poly(ADP-ribose) mediated signaling
- (2013) Tobias Karlberg et al. MOLECULAR ASPECTS OF MEDICINE
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
- (2012) Mike De Vos et al. BIOCHEMICAL PHARMACOLOGY
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Role of PARP Inhibitors in Cancer Biology and Therapy
- (2012) D. Davar et al. CURRENT MEDICINAL CHEMISTRY
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- PARP inhibitors attenuate chemotherapy-induced painful neuropathy
- (2012) Jill-Desiree Brederson et al. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
- (2009) J. P. Palma et al. CLINICAL CANCER RESEARCH
- Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
- (2009) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
- (2009) X. Liu et al. MOLECULAR CANCER RESEARCH
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hereditary breast cancer: new genetic developments, new therapeutic avenues
- (2008) Philippe M. Campeau et al. HUMAN GENETICS
- Chemotherapy-induced neuropathy
- (2008) Anthony J. Windebank et al. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started